GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Bohui Innovation Biotechnology Group Co Ltd (SZSE:300318) » Definitions » Net-Net Working Capital

Beijing Bohui Innovation Biotechnology Group Co (SZSE:300318) Net-Net Working Capital : ¥-2.64 (As of Mar. 2025)


View and export this data going back to 2012. Start your Free Trial

What is Beijing Bohui Innovation Biotechnology Group Co Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Beijing Bohui Innovation Biotechnology Group Co's Net-Net Working Capital for the quarter that ended in Mar. 2025 was ¥-2.64.

The industry rank for Beijing Bohui Innovation Biotechnology Group Co's Net-Net Working Capital or its related term are showing as below:

SZSE:300318's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 4.06
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Beijing Bohui Innovation Biotechnology Group Co Net-Net Working Capital Historical Data

The historical data trend for Beijing Bohui Innovation Biotechnology Group Co's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Bohui Innovation Biotechnology Group Co Net-Net Working Capital Chart

Beijing Bohui Innovation Biotechnology Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.30 -2.69 -2.34 -2.43 -2.60

Beijing Bohui Innovation Biotechnology Group Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.48 -2.49 -2.55 -2.60 -2.64

Competitive Comparison of Beijing Bohui Innovation Biotechnology Group Co's Net-Net Working Capital

For the Biotechnology subindustry, Beijing Bohui Innovation Biotechnology Group Co's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Bohui Innovation Biotechnology Group Co's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Bohui Innovation Biotechnology Group Co's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Beijing Bohui Innovation Biotechnology Group Co's Price-to-Net-Net-Working-Capital falls into.


;
;

Beijing Bohui Innovation Biotechnology Group Co Net-Net Working Capital Calculation

Beijing Bohui Innovation Biotechnology Group Co's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net-Net Working Capital(A: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(77.262+0.75 * 58.575+0.5 * 1011.258-1776.43
-0-970.442)/816.900
=-2.60

Beijing Bohui Innovation Biotechnology Group Co's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2025 is calculated as

Net-Net Working Capital(Q: Mar. 2025 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(286.845+0.75 * 71.866+0.5 * 1026.039-2032.224
-0-974.439)/816.900
=-2.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Beijing Bohui Innovation Biotechnology Group Co  (SZSE:300318) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Beijing Bohui Innovation Biotechnology Group Co Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Beijing Bohui Innovation Biotechnology Group Co's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Bohui Innovation Biotechnology Group Co Business Description

Traded in Other Exchanges
N/A
Address
Block G Jingxinyuan, NO.25 Jia Beiwucun Road, Haidian, Beijing, CHN, 100097
Beijing Bohui Innovation Biotechnology Group Co Ltd is a high-tech biomedical enterprise integrating R&D, production, sales, and after-sales service. The company focuses on the research and development, production, sales, and after-sales services of in vitro diagnostic products. The Company's business involved two segments: inspection and testing and biological products. The Biological segment generated the majority of its revenue which engaged in the research and development, production, and sales of blood products, the product range covers human blood albumin, human immunoglobulin, and human coagulation factor three categories of multiple varieties, basically covering the important varieties of blood products.
Executives
Niu Shu Hui Executives
Di Xiao Feng Director
Yang Qi Director
Lu Xin Qun Directors, executives
Zhang Lei Director
Wan Zhang Geng Executives
Song Rui Directors, executives

Beijing Bohui Innovation Biotechnology Group Co Headlines

No Headlines